Curriculum Vitaes
  1. Researcher Search Results
  2. Keiko Hikino

Keiko Hikino

  (曳野 圭子)

Profile Information

Affiliation
Department of Clinical Pharmacology and Therapeutics, The Jikei University School of Medicine, Tokyo, Japan
Visiting Research Scientist, Laboratory for Pharmacogenomics, RIKEN, Yokohama, JAPAN
Department of Statistical and Translational Genetics, Center for Genomic Medicine, Fujita Health University
Visiting Research Scientist, Clinical Research Center, Shizuoka General Hospital, Shizuoka, Japan
Degree
MD(Shimane University, Japan)
PhD(Apr, 2020, Yokohama City University, Japan)
Researcher number
10789580
ORCID ID
 https://orcid.org/0000-0002-4852-2401
J-GLOBAL ID
201901008820546985
researchmap Member ID
B000373995

Research Interests

 4

Research Areas

 2

Research History

 10
More

Committee Memberships

 2

Awards

 10

Papers

 39
  • Ludmila Prokunina-Olsson, Oscar Florez-Vargas, Michael G. Levin, Diptavo Dutta, Charles E. Breeze, Lauren M. Hurwitz, Wusheng Yan, Philippe Lamy, Brenen W. Papenberg, Kevin Wang, Chia-Han Lee, Roger L. Milne, Jian Gu, Caroline Y. Um, Vijai Joseph, Helena Furberg, Florence Le Calvez-Kelm, Adriana Lori, Parichoy Pal Choudhury, Nina Afshar, Manolis Kogevinas, Kenneth Offit, Sita H. Vermeulen, Evangelina López de Maturana, Demetrius Albanes, Mark P. Purdue, Victoria K. Cortessis, Margaret R. Karagas, Charles Kooperberg, Marc Bjurlin, Deborah A. Tadesse, Steven C. Moore, Wen-Yi Huang, Christopher A. Haiman, Mariana C. Stern, A. Heather Eliassen, Lorelei A. Mucci, Katja K. Aben, Tessel E. Galesloot, Tatjana Simic, Dejan Dragicevic, Arndt Hartmann, Veronika Weyerer, Danijel Sikic, Gregers G. Hermann, Karin Mogensen, Marcus Horstmann, Marc-Oliver Grimm, Roman Nawroth, Tobias Maurer, Ellen C. Zwarthoff, Kim E. M. van Kessel, Lars Dyrskjøt, Torben Ørntoft, Sia Viborg Lindskrog, Frederik Prip, Jørgen Bjerggaard Jensen, Ulrika Segersten, Per-Uno Malmström, Astrid C. Petersen, Anurag Verma, Soichiro Yoshino, Keiko Hikino, Chikashi Terao, Thorunn Rafnar, Koichi Matsuda, Taro Shuin, Montserrat Garcia-Closas, Francisco X. Real, Lambertus A. Kiemeney, Stephen J. Chanock, Núria Malats, Debra T. Silverman, Lars Dyrskjot, Nathaniel Rothman, Scott M. Damrauer, Stella Koutros, Jeffrey S. Damrauer
    Nature Communications, Aug 8, 2026  Peer-reviewed
  • Shunsuke Uchiyama, Takeo Saito, Xiaoxi Liu, Yuki Ishikawa, Keiko Hikino, Masashi Ikeda, Giulio Genovese, Nakao Iwata, Chikashi Terao
    Molecular Psychiatry, May, 2026  Peer-reviewed
  • Fei-Fei Cheng, Xiaoxi Liu, Hao Mi, Lizhong Wang, Ruilei Ma, Yazhou Guo, Julia Sidorenko, Chen Jiang, Tania Islam, Akira Meguro, Keiko Hikino, Yuki Ishikawa, Senwei Tang, Teng Li, Ruoyan Chen, Likun Wang, Reedik Mägi, Andres Metspalu, Estonian Biobank Research Team, Lili Milani, Tõnu Esko, Mari Nelis, Georgi Hudjashov, 23andMe Research Team, Adam Auton, Alan Kwong, Anjali J. Shastri, Barry Hicks, Catherine H. Weldon, David A. Hinds, Emily DelloRusso, Emily M. Rios, Joyce Y. Tung, Kahsaia de Brito, Katelyn Kukar Bond, Keng-Han Lin, Matthew H. McIntyre, Matthew J. Kmiecik, Qiaojuan Jane Su, Robert K. Bell, Sayantan Das, Shubham Saini, Stella Aslibekyan, Vinh Tran, Wanwan Xu, Alisa P. Lehman, Noura S. Abul-Husn, R. Ryanne Wu, Rebecca M. K. Berns, Ruth I. Tennen, Stacey B. Detweiler
    Nature Genetics, Apr 20, 2026  Peer-reviewed
  • Claire Moore, Melissa S Bourque, Andreas Halman, José A G Agúndez, Cynthia A Prows, Keiko Hikino, Matthias Schwab, Carolyn J Oxencis, Dharmisha Chauhan, Meta H M Diekstra, Susie E Long, Gillian C Bell, Andrea Gaedigk, Michelle Whirl-Carrillo, Teri E Klein, Kelly E Caudle, Rachel Conyers
    Clinical pharmacology and therapeutics, Apr 14, 2026  Peer-reviewed
    5-hydroxytryptamine type 3 (5-HT3) receptor antagonists are used to treat nausea and vomiting and in the prevention of chemotherapy-induced, radiation-induced, and postoperative nausea and vomiting. Most of the 5-HT3 receptor antagonists (i.e., ondansetron, tropisetron, dolasetron, palonosetron, and ramosetron) are metabolized by CYP2D6, but the extent of CYP2D6 involvement varies. CYP2D6 genetic variation can influence the metabolism of these medications, particularly ondansetron and tropisetron, thereby affecting drug efficacy. This guideline is an update to the 2016 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron and includes updated information on CYP2D6 genetic testing and evidence tables. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for 5-HT3 receptor antagonists based on CYP2D6 genotype, particularly where genetic variation is associated with reduced drug efficacy (updates at https://www.clinpgx.org/guideline/PA166251457).
  • Mary Feitosa, Karen Schwander, Clint Miller, Aldi Kraja, Amy Bentley, Michael Brown, Hannah de Hesselle, Raymond Noordam, Songmi Lee, Pavithra Nagarajan, Heming Wang, Ayush Giri, Farrah Ammous, Traci Bartz, Chiara Batini, Jean-Tristan Brandenburg, Max Breyer, Heather Cordell, Janie Corley, Latchezar Dimotrov, Anh Do, Jiawen Du, Franco Giulianini, Christopher Grace, Valborg Gudmundsdottir, Xiuqing Guo, Sarah Harris, Natalie Hasbani, Janina Herold, Keiko Hikino, Edith Hofer, Andrea Horimoto, Fang-Chi Hsu, Zhijie Huang, Anne Jackson, Chang Hoon Kang, Federica Laguzzi, Timo Lakka, Christophe Lefevre, Jian'an Luan, Leo-Pekka Lyytikäinen, Aline Meirhaeghe, Manon Muntaner, Masahiro Nakatochi, Giuseppe Giovanni Nardone, Ilja Nolte, Teresa Nutile, Nicholette Palmer, Amit Patki, Alessandro Pecori, Varun Rao
    Apr 3, 2026  
    <title>Abstract</title> <p>Genetic predisposition and alcohol consumption are risk factors for increased blood pressure (BP), but their interactions influencing BP remain understudied. We conducted population-specific and cross-population meta-analyses of genome-wide gene-alcohol (GxAlc) interactions affecting BP in &gt;1.1M individuals from multiple populations. We identified 46 GxAlc interaction loci for BP, including 21 from one-degree-of-freedom interaction tests (PGxAlc&lt;5x10-8; or &lt;0.05/Meff, Meff independent BP associations at P&lt;10-5), and 25 from two-degree-of-freedom tests of main and interaction effects (PGxAlc&lt;0.05/M2df, M2df independent 2df-associations at P2df&lt;5x10-8), including 7 novel and 39 known BP loci. The 12q24 locus highlights the genetic effect of BRAP-rs11066001 on BP, being ~6 times larger in current drinkers than in non-drinkers. Gene prioritization with 46 GxAlc loci identified 15 genes with ≥3 lines of evidence (location, literature, druggability, functional/regulatory annotation, or pathway analyses). Several loci showed sex- and population-specific effects and revealed biological pathways of alcohol’s influence on BP, suggesting mechanisms underlying alcohol-induced hypertension.</p>
More

Professional Memberships

 8
More

Research Projects

 7
More
To the list screen